InVivo Therapeutics to Present at Neuroscience 2016
November 10 2016 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) will
present data from its ongoing nonclinical study of Neuro-Spinal
Scaffold™ implantation at Neuroscience 2016, the Society for
Neuroscience 46th annual conference November 12-16 in San Diego.
The company’s oral presentation entitled “The Neuro-Spinal Scaffold
promotes tissue remodeling, axonal sprouting, and Schwann cell
myelination following acute spinal cord contusion injury in rats”
will be presented by Simon Moore, Ph.D., Director of Research, on
Monday, November 14 at 2:15 PM (PST) during the Brain and Spinal
Cord Injury nanosymposium.
“I look forward to sharing these latest Neuro-Spinal Scaffold
nonclinical findings with the neuroscience community,” Dr. Moore
said. “In the data to be presented at Neuroscience 2016, we examine
findings regarding spinal cord preservation, neural regeneration
and remyelination in animal models of spinal cord injury,
contributing to the growing body of spinal cord injury
research.”
This is the tenth scientific or medical meeting in which InVivo
Therapeutics or its collaborators have presented data from the
Neuro-Spinal Scaffold program this year.
“We continue to present exciting results from our research in
hopes of redefining the life of the spinal cord injury patient,”
said Mark Perrin, CEO of InVivo Therapeutics. “These data
illustrate the potential mechanisms of action of the Neuro-Spinal
Scaffold, which we are investigating clinically as a treatment
option for this underserved patient community.”
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in the INSPIRE pivotal probable
benefit study for the treatment of patients with complete (AIS A)
traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161110005345/en/
InVivo Therapeutics Holdings Corp.Brian Luque,
617-863-5535Investor Relationsbluque@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024